{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:33:45Z","timestamp":1793738025408,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.yebeh.2023.109384","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T07:30:13Z","timestamp":1692948613000},"page":"109384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Real-life evidence about the use of intravenous brivaracetam in urgent seizures: The BRIV-IV study"],"prefix":"10.1016","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2080-8042","authenticated-orcid":false,"given":"Vicente","family":"Villanueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1211-5107","authenticated-orcid":false,"given":"Xiana","family":"Rodriguez-Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Juiz-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6236-270X","authenticated-orcid":false,"given":"Debora","family":"Sayas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3582-060X","authenticated-orcid":false,"given":"Kevin","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ascensi\u00f3n","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Garc\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulce","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Rubio-Naz\u00e1bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8383-163X","authenticated-orcid":false,"given":"Alejandro","family":"Fern\u00e1ndez-Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Gifreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estevo","family":"Santamarina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Hern\u00e1ndez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e9","family":"Falip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Parejo-Carbonell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garc\u00eda-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Belen","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Massot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2195-9854","authenticated-orcid":false,"given":"Montserrat","family":"Asensio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5701-5583","authenticated-orcid":false,"given":"Juana","family":"Gim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Ruiz-Gim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Chavarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Rocamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Escalza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.yebeh.2023.109384_b0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","article-title":"Guidelines for the evaluation and management of status epilepticus","volume":"17","author":"Brophy","year":"2012","journal-title":"Neurocrit Care"},{"issue":"5","key":"10.1016\/j.yebeh.2023.109384_b0010","first-page":"353","article-title":"Emergency management of epileptic seizures: a consensus statement","volume":"32","author":"Garc\u00eda Morales","year":"2020","journal-title":"Emergencias"},{"issue":"5","key":"10.1016\/j.yebeh.2023.109384_b0015","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/ene.13885","article-title":"The ADAN scale: a proposed scale for pre-hospital use to identify status epilepticus","volume":"26","author":"Requena","year":"2019","journal-title":"Eur J Neurol"},{"issue":"10","key":"10.1016\/j.yebeh.2023.109384_b0020","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00415-008-0989-1","article-title":"Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy","volume":"255","author":"Rossetti","year":"2008","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.yebeh.2023.109384_b0025","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/ene.13073","article-title":"A new clinical score for the prognosis of status epilepticus in adults","volume":"23","author":"Gonz\u00e1lez-Cuevas","year":"2016","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109384_b0030","first-page":"245","article-title":"Adults discharged after an epileptic seizure: a model of 30-day risk for adverse outcomes","volume":"31","author":"Alonso Avil\u00e9s","year":"2019","journal-title":"Emergencias"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109384_b0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2023.109384_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107374","article-title":"Burden of disease in patients with a history of status epilepticus and their caregivers","volume":"112","author":"King-Stephens","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"5","key":"10.1016\/j.yebeh.2023.109384_b0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/jcm5050054","article-title":"Comparison of intravenous anesthetic agents for the treatment of refractory status epilepticus","volume":"5","author":"Reznik","year":"2016","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.yebeh.2023.109384_b0050","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus \u2013 report of the ILAE task force on classification of status epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.yebeh.2023.109384_b0055","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1056\/NEJM199809173391202","article-title":"A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group","volume":"339","author":"Treiman","year":"1998","journal-title":"N Engl J Med"},{"issue":"Suppl 8","key":"10.1016\/j.yebeh.2023.109384_b0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1528-1167.2011.03235.x","volume":"52","author":"Silbergleit","year":"2011","journal-title":"Epilepsia"},{"issue":"10231","key":"10.1016\/j.yebeh.2023.109384_b0065","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","article-title":"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial","volume":"395","author":"Chamberlain","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2023.109384_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109134","article-title":"Do acute EEG findings add to clinical features in predicting outcomes after status epilepticus and acute symptomatic seizures?","volume":"141","author":"Sivaraju","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109384_b0075","article-title":"Brivaracetam: a novel antiepileptic drug for focal-onset seizures","volume":"11","author":"Stephen","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"issue":"1\u20133","key":"10.1016\/j.yebeh.2023.109384_b0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2023.109384_b0085","first-page":"1","article-title":"A review of the pharmacology and clinical efficacy of brivaracetam","volume":"10","author":"Klein","year":"2018","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2023.109384_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116799","article-title":"Efficacy and tolerability of intravenous brivaracetam for status epilepticus: a systematic review","volume":"413","author":"Moalong","year":"2020","journal-title":"J Neurol Sci"},{"issue":"8","key":"10.1016\/j.yebeh.2023.109384_b0095","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/epi.13433","article-title":"Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus","volume":"57","author":"Stockis","year":"2016","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2023.109384_b0100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/epi.13267","article-title":"Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action","volume":"57","author":"Nicolas","year":"2016","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2023.109384_b0105","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/bjp.2008.198","article-title":"Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A","volume":"154","author":"Matagne","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.yebeh.2023.109384_b0110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/epi.14486","article-title":"Intravenous brivaracetam in status epilepticus: a retrospective single-center study","volume":"59","author":"Kalss","year":"2018","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2023.109384_b0115","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/epi.14476","article-title":"Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus","volume":"59","author":"Strzelczyk","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109384_b0120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eplepsyres.2018.12.001","article-title":"Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response","volume":"149","author":"Aicua-Rapun","year":"2019","journal-title":"Epilepsy Res"},{"issue":"8","key":"10.1016\/j.yebeh.2023.109384_b0125","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/epi.16094","article-title":"Use of intravenous brivaracetam in status epilepticus: a multicenter registry","volume":"60","author":"Santamarina","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109384_b0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.seizure.2021.01.014","article-title":"Intravenous brivaracetam in status epilepticus: a multicentric retrospective study in Italy","volume":"86","author":"Orlandi","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2023.109384_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107127","article-title":"Randomized open-label trial of intravenous brivaracetam versus lorazepam for acute treatment of increased seizure activity","volume":"109","author":"Szaflarski","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109384_b0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.seizure.2018.05.013","article-title":"Seizure cluster: definition, prevalence, consequences, and management","volume":"68","author":"Jafarpour","year":"2019","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.yebeh.2023.109384_b0145","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/epi.13409","article-title":"Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy","volume":"57","author":"Klein","year":"2016","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109384_b0150","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/ana.25249","article-title":"Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures","volume":"83","author":"Husain","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2023.109384_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.760855","article-title":"Clinical and economic outcomes of intravenous brivaracetam compared with levetiracetam for the treatment of seizures in United States hospitals","volume":"12","author":"Beaty","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2023.109384_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.954986","article-title":"Acute symptomatic seizures and status epilepticus in older adults: a narrative review focusing on management and outcomes","volume":"13","author":"Kong","year":"2022","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.yebeh.2023.109384_b0165","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/epi.14701","article-title":"A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers","volume":"60","author":"Finnema","year":"2019","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.yebeh.2023.109384_b0170","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1177\/08850666211073598","article-title":"Intravenous brivaracetam in the management of acute seizures in the hospital setting: a scoping review","volume":"37","author":"Lee","year":"2022","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.yebeh.2023.109384_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107088","article-title":"Indications for continuous electroencephalographic (cEEG) monitoring: what do they tell us?","volume":"190","author":"Zawar","year":"2023","journal-title":"Epilepsy Res"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023003037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023003037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:51:31Z","timestamp":1761504691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505023003037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":35,"alternative-id":["S1525505023003037"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109384","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life evidence about the use of intravenous brivaracetam in urgent seizures: The BRIV-IV study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109384"}}